We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dalton Pharma Services Licenses Thermo Fisher Scientific Enter Drug Development Agreement
News

Dalton Pharma Services Licenses Thermo Fisher Scientific Enter Drug Development Agreement

Dalton Pharma Services Licenses Thermo Fisher Scientific Enter Drug Development Agreement
News

Dalton Pharma Services Licenses Thermo Fisher Scientific Enter Drug Development Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dalton Pharma Services Licenses Thermo Fisher Scientific Enter Drug Development Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dalton Pharma Services and Thermo Fisher Scientific have entered into an agreement under which Dalton will use a proprietary Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use.

Utilizing enzyme-based technology developed at Thermo Fisher Scientific's Milwaukee, Wisconsin, molecular bioreagents facility, Dalton will produce poly-inosine (Poly-I) and poly-cytosine (Poly-C) in accordance with cGMP (current good manufacturing practice) regulations.

Poly-I and Poly-C are polynucleotides that are used as adjuvants, or catalysts, to stimulate an immune response when combined with other substances in a drug. Dalton will supply these polynucleotides to Oncovir, Inc that will use Poly-I and Poly-C in vaccine development.

"We are delighted to have this opportunity to work with Thermo Fisher Scientific in order to commercialize their novel biopolymers," said Peter Pekos, president and CEO of Dalton Pharma Services. "The agreement is timely due to an increased demand for commercial quantities of these molecules as adjuvants for new vaccines. And, this partnership recognizes Dalton's expertise in cGMP manufacturing and analysis of complex molecules under cGMP conditions."

"By working with partners like Dalton Pharma Services, our innovative technology is finding its way into new and exciting therapeutics," said Mitch Kennedy, global vice president and general manager of Thermo Fisher Scientific's Genomics business.

"Ultimately, this allows Thermo Fisher Scientific to advance our mission as a company, which is to enable our customers to make the world healthier, cleaner and safer," Kennedy added.

Advertisement